0.00Open0.00Pre Close0 Volume0 Open Interest17.50Strike Price0.00Turnover139.37%IV-22.38%PremiumJan 17, 2025Expiry Date3.20Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6755Delta0.0779Gamma3.58Leverage Ratio-0.0411Theta-0.0064Rho-2.41Eff Leverage0.0120Vega
Arcutis Biotherapeutics Stock Discussion
Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Rubric Capital Management LP(9.38%),David Rosen(9.38%)
Long-term! 😜
1 MINUTE AGO, 8:20 AM EDT
VIA GLOBENEWSWIRE
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types | ARQT Stock News
No comment yet